Show simple item record

dc.contributor.authorNnamani, Petra
dc.contributor.authorUgwu, Agatha
dc.contributor.authorIbezim, Emmanuel
dc.contributor.authorOnoja, Simon
dc.contributor.authorOdo, Amelia
dc.contributor.authorWindbergs, Maike
dc.contributor.authorRossi, Chiara
dc.contributor.authorLehr, Claus-Michael
dc.contributor.authorAttama, Anthony
dc.date.accessioned2019-04-02T13:20:06Z
dc.date.available2019-04-02T13:20:06Z
dc.date.issued2019-02-13
dc.identifier.issn1464-5246
dc.identifier.pmid30758259
dc.identifier.doi10.1080/02652048.2019.1582724
dc.identifier.urihttp://hdl.handle.net/10033/621737
dc.description.abstractCONTEXT: In this study, controlled ciprofloxacin (CIPRO) nanostrustructured lipid carriers of Precirol® ATO 5/Transcutol® HP (batch A) and tallow fat/Transcutol® HP (batch B) was carreid out. OBJECTIVE: The aim was to improve solubility and bioavailability of CIPRO. OBJECTIVE: Study of controlled ciprofloxacin (CIPRO) nanostructured lipid carriers of Precirol® ATO 5/Transcutol® HP (batch A) and tallow fat/Transcutol® HP (batch B). METHODS: CIPRO concentrations C1-5 (0.0, 0.2, 0.5, 0.8, and 1.0% w/w) as AC1-5 and BC1-5 were prepared by hot homogenisation and characterised by zetasizer, differential scanning calorimetry, Fourier transform infra-red spectroscopy, in vitro drug release and growth inhibitory zone diameter (IZD) on agar-seeded Bacillus subtilis. RESULTS: AC5 achieved polydispersed particles of ∼605 nm, 92% encapsulation efficiency (EE) and -28 mV similar to BC5 (∼789 nm, 91% EE, and -31 mV). Crystallinity indices (AC5 and BC5) were low at 3 and 5%, respectively. CIPRO release in AC5 was ∼98% in SGF (pH 1.2) and BC5 similarly ∼98% in SIF (pH 6.8). CONCLUSIONS: AC5 had superior growth inhibition of B. subtilis at lower concentration (1.2 µg/mL) than BC5 and CIPRO controls; hence could serve as possible sustained delivery system of CIPRO.en_US
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectInhibition zone diameteren_US
dc.subjectantimicrobial activityen_US
dc.subjectciprofloxacinen_US
dc.subjectnanostructured lipid carriersen_US
dc.titlePreparation, characterisation and in vitro antibacterial property of ciprofloxacin-loaded nanostructured lipid carrier for treatment of Bacillus subtilis infection.en_US
dc.typeArticleen_US
dc.contributor.departmentHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalJournal of Microencapsulationen_US
dc.source.journaltitleJournal of microencapsulation


Files in this item

Thumbnail
Name:
Nnamani et al.pdf
Size:
582.9Kb
Format:
PDF
Description:
original manuscript

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International